Leading the Way at Weill Cornell—daedalusfund

Scientific Advisory Committee

Arthur Bertelsen, PhD retired in 2020 as Vice President, Research Collaborations at Bristol-Myers Squibb Research, a position he held beginning in 2010. In this role, Art has overall responsibility for the management of external research collaborations across all therapeutic areas. Art provides guidance and direction on the formation of new collaborations consistent with the strategic objectives of BMS Research and his group provides alliance management for external relationships until the programs transition to full development. This role includes externalization of BMS technology and early stage assets for collaborative development. Art represents BMS as a member of the managing board of Allied-Bristol Life Sciences, LLC. Prior to joining BMS, Art spent more than twelve years at Schering-Plough Research Institute, where he was responsible for all aspects of forming and managing external collaborations to discover therapeutics or integrate new technology into discovery operations. Prior to joining SPRI Art served as SVP of Research for PharmaGenics, Inc., an oncology-focused biotech company that was acquired by Genzyme in 1997. Trained as a cellular and molecular biologist, before PharmaGenics, Art led research directed toward recombinant protein discovery and development, particularly focused on post-translational modification of peptide/protein therapeutics.

Dr. Bertelsen holds an AB in biochemical sciences from Princeton University and received his MS and PhD degrees from the program for Cellular and Molecular Biology at New York University Medical Center.

Bruce Leuchter, MD Dr. Bruce Leuchter is a Managing Director at PJT Partners where he provides M&A and capital markets advisory services to companies in the life science industry with a focus on the biotechnology sector. Dr. Leuchter is a physician by training and Neuropsychiatrist by specialty. He completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a Diplomate of the American Board of Psychiatry and Neurology. Dr. Leuchter served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College and maintains a faculty appointment of Clinical Assistant Professor of Psychiatry. Dr. Leuchter's financial services experience, prior to joining PJT Partners, includes roles in equity research and investment banking at Goldman Sachs and Credit Suisse, respectively. Given his background in neuroscience, he frequently advises companies developing technologies for diseases of the brain and nervous system. Dr. Leuchter co-founded Click Therapeutics, a digital medicine company which engineers, validates and commercializes digital therapeutics across disease areas with a focus on neuropsychiatry. He serves as a member of the Scientific Advisory Committee for the Daedalus Fund for Innovation at Weill Cornell Medical College, and on the Leadership Council of the Life Science Institute at the University of Michigan.

Ellen Lubman Ellen Lubman is the founder of Bella Biotech LLC, an advisory firm providing counsel to early stage biotech companies in capital raising, mergers and acquisitions and partnering strategies.

Previously, she was Vice President of External Science and Innovation at Allergan, Inc. Ellen came to Allergan after joining predecessor company, Forest Laboratories, in February 2014 as Vice President, Strategy and Innovation

Ellen has 15+ years of experience throughout the biopharmaceutical industry. Ellen started her career as a pharmaceutical representative with Abbott Laboratories then joined investment banking firm, Robertson Stephens, as a Biotechnology equity research analyst during the height of the genomics revolution, focused on early stage drug discovery and development companies. After completing her MBA from Stanford Graduate School of Business with a focus on Global Management, Ellen joined as a founding member of a biotechnology private equity fund, Celtic Pharma. Ellen has worked with venture capital funds, seed-stage, biotech and pharma companies, in business and corporate development, operations and strategy roles, including Amgen, Kadmon Corporation and Bristol-Myers Squibb where she was instrumental in executing on the "String of Pearls" targeted growth strategy.

Ellen is on the Board of Directors of GeneCentric, an innovative oncology company, and Gilda’s Club of New York, an Advisory Board Member for Springboard Enterprises’ Life Sciences Team, an active member of Women in Bio Metro Chapter, and advised multiple early stage start-up companies. She is also on the Scientific Advisory Board of the Daedalus Innovation Fund at Weill-Cornell.

Gene Marcantonio, MD, PhD is currently President and Chief Medical Officer of ARMGO Pharma, Inc, a small biotech specializing in compounds that normalize leaky RyR channels. Prior to joining ARMGO he was Associate Vice President in Translational Pharmacology at Merck and Company. He was leading the efforts in early stage development for Infectious Diseases, Vaccines and Immunology. He has led programs in these and other areas in early stage clinical development in Merck since 2007. Previously, Dr. Marcantonio was a tenured faculty member of the College of Physicians & Surgeons of Columbia University in the Department of Pathology and Cell Biology where he led an active research effort on integrin receptor signaling and function. He was also an attending physician at New York Presbyterian Hospital and the director of the autopsy service. He received his pathology training at the Brigham &Women’s Hospital of Harvard Medical School and postdoctoral training at MIT. He received his MD PhD from NYU School of Medicine.

Jonathan Mandelbaum, PhD is a Senior Associate on the venture capital team at OrbiMed. Prior to joining OrbiMed, he worked at Accelerator Life Science Partners, a company creation-focused venture capital investment vehicle, where he held responsibilities ranging from investment due diligence through operational roles. He previously worked as a research scientist in the oncology drug discovery unit at Millennium Pharmaceuticals. Dr. Mandelbaum received a B.Sc. from McGill University, and a Ph.D. in Cellular, Molecular and Biophysical Studies from Columbia University.

Carlo Rizzuto, PhD, is a Partner at Versant Ventures, based in New York City. Since joining the firm as a Principal in 2012, he has been involved in launching and investing in a number of Versant’s portfolio companies including Quentis, VenatoRx, Repare, Pandion, Jnana and Gotham. Carlo has been instrumental in establishing Versant’s presence in the Northeast including Highline Therapeutics, Versant's New York City-based Discovery Engine. Prior to opening the NYC office, Carlo led negotiations to establish a strategic partnership with Astellas that led to the creation of the Anokion spinoff, Kanyos.

Andrew Schiff, MD joined Aisling Capital at its inception and currently serves as one of the Managing Partners. Prior to Aisling Capital, Dr. Schiff practiced internal medicine for six years at New-York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of Aclaris Therapeutics, ARMGO Pharma and PowerVision.

Prior Board service includes Adams Respiratory Therapeutics, Agile Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision, CardioKine, Cempra Pharmaceuticals, Miramar Labs, Myogen, SkinMedica, Sirion Therapeutics, TransEnterix , Zeltiq Aesthetics, Quintiles (Board observer) and Zavante (Board observer). He is a supporter and Board member of the Visiting Nurse Service of New York and the Academy of American Poets.

Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his B.S. with honors in Neuroscience from Brown University.

Benny Soffer, MD joined Consonance Capital in September of 2005 and currently serves as a Partner and co-Portfolio Manager. Prior to joining Consonance, Benny completed a residency in Internal Medicine at Yale-New Haven Hospital in 2002 and subsequently served as an Attending Physician from 2002-2005. In addition to his work as a physician, Benny served as Medical Director of Clinical Process Improvement and as Interim Medical Director of Medical Information Systems. Benny is currently a Clinical Assistant Professor of Medicine at Weill Cornell Medicine. Benny is a graduate of Williams College, where he received his BA in history, of Emory University, where he received his MD, and of Yale University, where he received his MBA.

Robert Spiegel, MD, FACP, is the former Chief Medical Officer of Schering Plough and was involved in the filing of over 30 New Drug Applications and interacted with regulatory authorities in the U.S. and globally, serving on the executive committees overseeing all research projects and drug licensing activities. Since 2010 he has served on the Board of Directors and Scientific Advisory Committees of a number of public and private Biotech companies and organizations. He also serves as an advisor to Warburg Pincus and the Israel Biotech Fund. He currently serves on the Board of Directors of Geron Corporation, Edge Therapeutics, and Cyclacel Pharmaceuticals and the private companies Neximmune and Vidac Pharmaceuticals.

Andrew Weisenfeld has been an investment banker since 1989. He became a Partner at MTS Health Partners in January 2008, primarily responsible for the development of the life sciences and medical technology practices. Previously, Mr. Weisenfeld was a Managing Director in Banc of America Securities’ Corporate and Investment Banking Healthcare Group. Prior to joining Bank of America in 2003, Mr. Weisenfeld was a Managing Director at JP Morgan and its predecessor company, Chase Securities, leading its Healthcare M&A business across all sectors of healthcare from 1997 to 2003. Prior to joining Chase, Mr. Weisenfeld spent over five years in the M&A Group at Merrill Lynch. Throughout his career, Mr. Weisenfeld has worked on a wide range of advisory transactions including acquisitions, sale transactions and strategic relationships and has also been responsible for many life sciences financings. Mr. Weisenfeld is a board member of Public Health Solutions, a New York based not-for-profit. An active alumnus of Cornell University, he serves as a member of Weill Cornell’s Dean’s Council and is also a member of the Cornell Dyson School’s Undergraduate Program Advisory Council. Mr. Weisenfeld holds an MBA from The Wharton School at the University of Pennsylvania and a BS from Cornell University.

Emeritus Members:

Ben Bronstein, MD has deep-domain expertise in the ophthalmology space and spent over 30 years in entrepreneurial roles in life science companies and in venture capital firms. He is a founder and sole proprietor of Cold Spring Venture Advisors, and has he served as an independent consultant to life science companies. Most recently, he was executive vice president of Aclaris Therapeutics. Earlier, he was Chief Medical Officer of Stealth BioTherapeutics, a privately held company developing pharmaceuticals for serious diseases associated with mitochondrial dysfunction. Prior to Stealth he was a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School. Dr. Bronstein has founded and/or held senior management positions in a number of life science firms, including OKPO Health, a publicly traded company developing human therapeutics and diagnostics and Vidus Ocular, Inc., a Yale University spinout developing an implantable device for the treatment of glaucoma. He has also held senior roles in life science investment firms including as a founder and senior vice president of Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc. Dr. Bronstein serves on the boards of directors of publicly and privately held life science companies. He is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He received his M.D. and M.B.A. from Boston University.

Richard Pasternak, MD served as the founding chair of the Daedalus Fund Scientific Advisory Committee (SAC) from 2014 through 2020. He has deep-domain expertise in the cardiovascular space. Dr. Pasternak retired from Merck in 2010, having served as Vice President, Clinical Research and Head, Cardiovascular Therapeutic Area (2004-2008), and Vice President, Head of Global Scientific Affairs and Scientific Leadership (2008-2010). Dr. Pasternak also served as a key Senior Executive in a communications role for Merck regarding critical issues related to scientific affairs and was a policy liaison for medical and scientific issues. Prior to joining Merck, Dr. Pasternak was Director of Preventive Cardiology and Cardiac Rehabilitation at the Massachusetts General Hospital, Director of the Cardiology Practice Plan, as an Associate Professor of Medicine at Harvard Medical School, and as a Clinical Professor of Medicine at Weill Cornell Medicine.

Both Dr. Bronstein and Dr. Pasternak have committed to serving as consultants to the SAC in their respective areas.